Chemotherapy Principles NCLEX — Safe Handling Myelosuppression Neutropenia Nursing | NurseNest

Chemotherapy Principles NCLEX — Safe Handling Myelosuppression Neutropenia Nursing | NurseNest

Key Concepts

Chemotherapy Principles Overview

Mechanism Categories: | Class | Examples | Mechanism | |---|---|---| | Alkylating agents | Cyclophosphamide, cisplatin, carboplatin | Cross-link DNA → prevent replication | | Antimetabolites | Methotrexate, 5-fluorouracil, cytarabine | Mimic nucleotides → inhibit DNA/RNA synthesis | | Anthracyclines | Doxorubicin (Adriamycin), daunorubicin | DNA intercalation + free radical damage | | Taxanes | Paclitaxel (Taxol), docetaxel | Stabilize microtubules → prevent mitosis | | Vinca alkaloids | Vincristine, vinblastine | Destroy microtubules → prevent mitosis | | Topoisomerase inhibitors | Etoposide, irinotecan | Block DNA unwinding enzymes | | Targeted therapy | Imatinib (Gleevec), trastuzumab (Herceptin) | Specific molecular targets | | Immunotherapy | Pembrolizumab (Keytruda), nivolumab | Immune checkpoint inhibition | Cell cycle specificity: - Cell cycle non-specific: alkylating agents, anthracyclines → effective regardless of phase - Cell cycle specific: antimetabolites (S phase), taxanes/vinca (M phase) → timed dosing On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit. If the stem names a license or role, reread that line; scope errors are classic trap answers even when the clinical topic...

Chemotherapy Toxicities

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Signs and Symptoms

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Red Flags / Danger Signs

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Safe Handling and Nursing Priorities

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Clinical Pearls & Exam Tips

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Client Education

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Your exam focus

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Next steps

Additional clinical detail, exam hooks, and takeaways continue in the full lesson.

Unlock full lesson + practice questions

8 more sections with scenarios, priorities, and review drills.

Start free trial Sign in

Retention & exam readiness

Clinical pearls, traps, safety priorities, quick recall, and related concepts live here so the main lesson stays calm and uninterrupted.

Review after learning, not during it.

Topic overview

NCLEX oncology pharmacology: chemotherapy cell cycle, myelosuppression nadir, safe handling requirements, neutropenic fever emergency, antiemetics, nursing priorities.

Clinical reasoning

For Chemotherapy Principles and Safe Handling, connect the assessment cue to the immediate risk before selecting an action for PN. Start with stability, ABCs, neurologic change, medication risk, infection risk, and scope of practice. Then decide whether the safest next step is assess, intervene, escalate, teach, or evaluate response.

Patient safety implications

A missed priority in Chemotherapy Principles and Safe Handling can delay recognition of deterioration or allow preventable harm to continue. Protect the client first by verifying abnormal cues, using ordered precautions, escalating unstable findings, and reassessing after intervention.

Example application

Next study step

Continue Your Learning

Finish the lesson first, then choose a focused activity to apply what you just reviewed.

Practice QuestionsApply this topic with board-style rationales.Open activity

Continue studying

Review Flashcards Practice Related Questions Continue Weak Area Recovery Recommended Next Lesson Take A Readiness Quiz

Practice this topic

Flashcards (same topic)Topic practice tests Adaptive practice test (weak areas)← All lessons

Sign in to save progress on this lesson.

Chemotherapy Principles Overview: Mechanism Categories: | Class | Examples | Mechanism | |---|---|---| | Alkylating agents | Cyclophosphamide, cisplatin, carboplatin | Cross-link DNA → prevent replication | | Antimetabolites | Methotrexate, 5-fluorouracil, cytarabine | Mimic nucleotides → inhibit DNA/RNA synthesis | | Anthracyclines | Doxorubicin (Adriamycin), daunorubicin | DNA intercalation + free radical damage | | Taxanes | Paclitaxel (Taxol), docetaxel | Stabilize microtubules → prevent mitosis | | Vinca alkaloids | Vincristine, vinblastine | Destroy microtubules → prevent mitosis | | Topoisomerase inhibitors | Etoposide, irinotecan | Block DNA unwinding enzymes | | Targeted therapy | Imatinib (Gleevec), trastuzumab (Herceptin) | Specific molecular targets | | Immunotherapy | Pembrolizumab (Keytruda), nivolumab | Immune checkpoint inhibition | Cell cycle specificity: - Cell cycle non-specific: alkylating agents, anthracyclines → effective regardless of phase - Cell cycle specific: antimetabolites (S phase), taxanes/vinca (M phase) → timed dosing On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Chemotherapy Principles Overview: Mechanism Categories: | Class | Examples | Mechanism | |---|---|---| | Alkylating agents | Cyclophosphamide, cisplatin, carboplatin | Cross-link DNA → prevent replication | | Antimetabolites | Methotrexate, 5-fluorouracil, cytarabine | Mimic nucleotides → inhibit DNA/RNA synthesis | | Anthracyclines | Doxorubicin (Adriamycin), daunorubicin | DNA intercalation + free radical damage | | Taxanes | Paclitaxel (Taxol), docetaxel | Stabilize microtubules → prevent mitosis | | Vinca alkaloids | Vincristine, vinblastine | Destroy microtubules → prevent mitosis | | Topoisomerase inhibitors | Etoposide, irinotecan | Block DNA unwinding enzymes | | Targeted therapy | Imatinib (Gleevec), trastuzumab (Herceptin) | Specific molecular targets | | Immunotherapy | Pembrolizumab (Keytruda), nivolumab | Immune checkpoint inhibition | Cell cycle specificity: - Cell cycle non-specific: alkylating agents, anthracyclines → effective regardless of phase - Cell cycle specific: antimetabolites (S phase), taxanes/vinca (M phase) → timed dosing On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Chemotherapy Principles Overview: Mechanism Categories: | Class | Examples | Mechanism | |---|---|---| | Alkylating agents | Cyclophosphamide, cisplatin, carboplatin | Cross-link DNA → prevent replication | | Antimetabolites | Methotrexate, 5-fluorouracil, cytarabine | Mimic nucleotides → inhibit DNA/RNA synthesis | | Anthracyclines | Doxorubicin (Adriamycin), daunorubicin | DNA intercalation + free radical damage | | Taxanes | Paclitaxel (Taxol), docetaxel | Stabilize microtubules → prevent mitosis | | Vinca alkaloids | Vincristine, vinblastine | Destroy microtubules → prevent mitosis | | Topoisomerase inhibitors | Etoposide, irinotecan | Block DNA unwinding enzymes | | Targeted therapy | Imatinib (Gleevec), trastuzumab (Herceptin) | Specific molecular targets | | Immunotherapy | Pembrolizumab (Keytruda), nivolumab | Immune checkpoint inhibition | Cell cycle specificity: - Cell cycle non-specific: alkylating agents, anthracyclines → effective regardless of phase - Cell cycle specific: antimetabolites (S phase), taxanes/vinca (M phase) → timed dosing On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.

Chemotherapy Principles Overview: Mechanism Categories: | Class | Examples | Mechanism | |---|---|---| | Alkylating agents | Cyclophosphamide, cisplatin, carboplatin | Cross-link DNA → prevent replication | | Antimetabolites | Methotrexate, 5-fluorouracil, cytarabine | Mimic nucleotides → inhibit DNA/RNA synthesis | | Anthracyclines | Doxorubicin (Adriamycin), daunorubicin | DNA intercalation + free radical damage | | Taxanes | Paclitaxel (Taxol), docetaxel | Stabilize microtubules → prevent mitosis | | Vinca alkaloids | Vincristine, vinblastine | Destroy microtubules → prevent mitosis | | Topoisomerase inhibitors | Etoposide, irinotecan | Block DNA unwinding enzymes | | Targeted therapy | Imatinib (Gleevec), trastuzumab (Herceptin) | Specific molecular targets | | Immunotherapy | Pembrolizumab (Keytruda), nivolumab | Immune checkpoint inhibition | Cell cycle specificity: - Cell cycle non-specific: alkylating agents, anthracyclines → effective regardless of phase - Cell cycle specific: antimetabolites (S phase), taxanes/vinca (M phase) → timed dosing On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit.